Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript

SA Transcripts 161.93K Followers Follow Telix Pharmaceuticals Limited ( TLX ) Q2 2026 Earnings Call August 19, 2026 7:00 PM EDT Company Participants Kyahn Williamson - Senior Vice President of Corporate Communications & Investor Relations Christian Behrenbruch - Co-Founder, MD, Group CEO & Executive Director Darren Smith - Group Chief Financial Officer Kevin Richardson - Chief Executive Officer of Telix Precision Medicine David Cade - Group Chief Medical Officer Conference Call Participants Chris Cooper - JPMorgan Chase & Co, Research Division Laura Sutcliffe - Citigroup Inc., Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division David Low - UBS Investment Bank, Research Division David Stanton - Jefferies LLC, Research Division Melissa Benson - Barrenjoey Markets Pty Limited, Research Division Dennis Hulme - Taylor Collison Limited, Research Division Presentation Kyahn Williamson Senior Vice President of Corporate Communications & Investor Relations Good morning, and good evening, everybody. My name is Kyahn Williamson, SVP of Investor Relations and Corporate Communications at Telix, and it's my pleasure to welcome you today to our H1 2026 Interim Results Presentation and Call. You'll have seen our documents lodged on the ASX earlier this morning. Next slide, please. Today, on our call, we'll be joined by Dr. Christian Behrenbruch, Managing Director and Group CEO; Darren Smith, our Group Chief Financial Officer; Kevin Richardson, CEO of the Telix Precision Medicine business; and Dr. David Cade, Chief Medical Officer. Following prepared remarks, we will open up the call to Q&A, starting with calls on the conference line. If we don't get your questions during the call, we will respond to you after the call is finished. Just to move to the next slide, please. Brief note, please note that today's presentation includes forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that relate to, among other things, anticipated future events, financial performance, plans, strategies and business developments. These forward-looking statements are based on current information, assumptions and